Vesicant characteristics of oxapliplatin following antecubital extravasation

J. G. Kennedy, J. P. Donahue, Bang H. Hoang, P. J. Boland

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Oxaliplatin is a novel class of platinum chermotherapeutic agent used in refractory adenocarcinoma. It has previously been regarded as a non-vesicant, and as such was considered safe to administer through peripheral veins. This report documents severe muscle and subcutaneous reaction with a single dose of oxaliplatin at the site of extravasation in a patient aged 58 years. Conventional therapeutic modalities were employed to reduce the effect of the soft tissue infiltrate. Despite that, significant muscle necrosis and fibrosis occurred. Surgery was deferred secondary to patient choice, and eventual extensive physical therapy restored function to the elbow joint. This case shows that oxaliplatin may not be an appropriate cytotoxic agent to be administered through a peripheral line and consideration must be made for central access when this drug is used. In addition, when extravasation does occur, the current report indicates that non-surgical management can be successful.

Original languageEnglish (US)
Pages (from-to)237-239
Number of pages3
JournalClinical Oncology
Volume15
Issue number5
DOIs
StatePublished - Aug 2003
Externally publishedYes

Fingerprint

oxaliplatin
Irritants
Elbow Joint
Muscles
Cytotoxins
Platinum
Veins
Adenocarcinoma
Fibrosis
Necrosis
Therapeutics
Pharmaceutical Preparations

Keywords

  • Extravasation
  • Oxaliplatin

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Vesicant characteristics of oxapliplatin following antecubital extravasation. / Kennedy, J. G.; Donahue, J. P.; Hoang, Bang H.; Boland, P. J.

In: Clinical Oncology, Vol. 15, No. 5, 08.2003, p. 237-239.

Research output: Contribution to journalArticle

Kennedy, J. G. ; Donahue, J. P. ; Hoang, Bang H. ; Boland, P. J. / Vesicant characteristics of oxapliplatin following antecubital extravasation. In: Clinical Oncology. 2003 ; Vol. 15, No. 5. pp. 237-239.
@article{8e78daeaa776498ebddaaf878711e619,
title = "Vesicant characteristics of oxapliplatin following antecubital extravasation",
abstract = "Oxaliplatin is a novel class of platinum chermotherapeutic agent used in refractory adenocarcinoma. It has previously been regarded as a non-vesicant, and as such was considered safe to administer through peripheral veins. This report documents severe muscle and subcutaneous reaction with a single dose of oxaliplatin at the site of extravasation in a patient aged 58 years. Conventional therapeutic modalities were employed to reduce the effect of the soft tissue infiltrate. Despite that, significant muscle necrosis and fibrosis occurred. Surgery was deferred secondary to patient choice, and eventual extensive physical therapy restored function to the elbow joint. This case shows that oxaliplatin may not be an appropriate cytotoxic agent to be administered through a peripheral line and consideration must be made for central access when this drug is used. In addition, when extravasation does occur, the current report indicates that non-surgical management can be successful.",
keywords = "Extravasation, Oxaliplatin",
author = "Kennedy, {J. G.} and Donahue, {J. P.} and Hoang, {Bang H.} and Boland, {P. J.}",
year = "2003",
month = "8",
doi = "10.1016/S0936-6555(02)00338-2",
language = "English (US)",
volume = "15",
pages = "237--239",
journal = "Clinical Oncology",
issn = "0748-7983",
publisher = "W.B. Saunders Ltd",
number = "5",

}

TY - JOUR

T1 - Vesicant characteristics of oxapliplatin following antecubital extravasation

AU - Kennedy, J. G.

AU - Donahue, J. P.

AU - Hoang, Bang H.

AU - Boland, P. J.

PY - 2003/8

Y1 - 2003/8

N2 - Oxaliplatin is a novel class of platinum chermotherapeutic agent used in refractory adenocarcinoma. It has previously been regarded as a non-vesicant, and as such was considered safe to administer through peripheral veins. This report documents severe muscle and subcutaneous reaction with a single dose of oxaliplatin at the site of extravasation in a patient aged 58 years. Conventional therapeutic modalities were employed to reduce the effect of the soft tissue infiltrate. Despite that, significant muscle necrosis and fibrosis occurred. Surgery was deferred secondary to patient choice, and eventual extensive physical therapy restored function to the elbow joint. This case shows that oxaliplatin may not be an appropriate cytotoxic agent to be administered through a peripheral line and consideration must be made for central access when this drug is used. In addition, when extravasation does occur, the current report indicates that non-surgical management can be successful.

AB - Oxaliplatin is a novel class of platinum chermotherapeutic agent used in refractory adenocarcinoma. It has previously been regarded as a non-vesicant, and as such was considered safe to administer through peripheral veins. This report documents severe muscle and subcutaneous reaction with a single dose of oxaliplatin at the site of extravasation in a patient aged 58 years. Conventional therapeutic modalities were employed to reduce the effect of the soft tissue infiltrate. Despite that, significant muscle necrosis and fibrosis occurred. Surgery was deferred secondary to patient choice, and eventual extensive physical therapy restored function to the elbow joint. This case shows that oxaliplatin may not be an appropriate cytotoxic agent to be administered through a peripheral line and consideration must be made for central access when this drug is used. In addition, when extravasation does occur, the current report indicates that non-surgical management can be successful.

KW - Extravasation

KW - Oxaliplatin

UR - http://www.scopus.com/inward/record.url?scp=0042130339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042130339&partnerID=8YFLogxK

U2 - 10.1016/S0936-6555(02)00338-2

DO - 10.1016/S0936-6555(02)00338-2

M3 - Article

C2 - 12924452

AN - SCOPUS:0042130339

VL - 15

SP - 237

EP - 239

JO - Clinical Oncology

JF - Clinical Oncology

SN - 0748-7983

IS - 5

ER -